Learn about the Hysterosalpingo Foam Sonography (HyFoSy) Procedure at the ACOG 2022 Annual Clinic and Scientific Meeting being held in San Diego, California. This year the meeting takes place at the San Diego Convention Center from May 6 – May 8, 2022. We welcome you to visit our booth #1213 where you can meet one-on-one with team members to discuss the HyFoSy ultrasound tubal patency procedure using ExEm® Foam. Team members will be discussing new offerings, reimbursement programs, and product ordering.
We are proud to be a part of this exciting meeting showcasing educational and engaging content for this professional OBGYN community dedicated to improving women’s health. We support ACOG’s mission in advocating for members and patients.
About the American College of Obstetricians and Gynecologists (ACOG)
Founded in 1951, ACOG is the premier professional membership organization for obstetrician–gynecologists. The College produces practice guidelines for health care professionals and educational materials for patients, provides practice management and career support, facilitates programs and initiatives to improve women’s health, and advocates for members and patients.
With more than 60,000 members spanning the entire career life cycle, ACOG is composed of 12 Districts. These Districts are made up of 98 Sections. ACOG’s Districts and Sections represent various regions, countries, territories, and states in North and South America.
ACOG Fellows are board-certified obstetrician-gynecologists whose professional activities are devoted to the practice of obstetrics and gynecology, who possess unrestricted licenses to practice medicine, and who have attained high ethical and professional standing.
To learn more about ACOG and the 2022 Annual Clinic and Scientific Meeting, visit: www.acog.org
About ExEm® Foam (air polymer-type A) intrauterine foam
ExEm® Foam ((air polymer-type A) intrauterine foam) is an innovative, FDA-approved product that offers a less invasive ultrasound procedure, a highly accurate alternative to other tubal patency assessment procedures, like laparoscopy or X-ray HSG. The contrast agent allows for easy recognition of tubal patency using the Foam procedure. During the tubal patency procedure, the foam is infused into the uterus by a healthcare professional to allow for visual assessment of fallopian tubes. If the tubes are patent the foam will appear as a thin, bright white line within the fallopian tubes and spill over the ovaries and into the peritoneal cavity when visualized with ultrasound. If the white line does not appear, the fallopian tubes might be occluded or blocked.
IMPORTANT SAFETY INFORMATION
ExEm® Foam should not be used on patients who are pregnant, have known or suspected lower genital tract inflammation or infection, have had a gynecologic procedure within the last 30 days, have vaginal bleeding, or have known or suspected reproductive tract neoplasia. Common side effects include pelvic and abdominal pain, vasovagal reactions (and associated symptoms such as nausea and faintness), and post-procedure spotting.
Click here for full prescribing information.
About ExEm® Foam Inc
ExEm® Foam Inc is focused on providing solutions to simplify infertility diagnosis and enhance the fertility journey. Drawing on its years of experience, the team develops innovative products that better meet the needs of today’s patient and healthcare professional. ExEm® Foam, the company’s first FDA-approved product, is indicated as a contrast drug for hysterosalpingo foam sonography, also known as HyFoSy, to assess whether there may be a blockage in the fallopian tubes in women with known or suspected infertility. ExEm® Foam has been used to assess more than 1,000,000 (and counting) fallopian tubes globally for tubal patency since it first launched in Europe in 2011. ExEm® Foam Inc is headquartered in Nashville, TN.
For more information, please visit www.exemfoam.com.
